Mezigdomide and dexamethasone for Multiple Myeloma

Exciting updates from Bristol Myers Squibb on #mezigdomide (#CC92480) in combination with tazemetostat and dexamethasone for multiple myeloma! #Mezigdomide, a potent #CELMoD under investigation, has shown promising preclinical results, being significantly more potent than #iberdomide and other #IMiDs. In the CA057-003 trial (#NCT05372354), 13 patients who had undergone a median of 5 prior lines of therapy received #mezigdomide, #tazemetostat, and #dexamethasone. The overall response rate (ORR) was 53.8%, with higher mezigdomide doses yielding an ORR of 71.4%. The combination demonstrated a manageable safety profile, with grade 3/4 TEAEs occurring in 69.2% of patients. Notably, mezigdomide rapidly degrades Ikaros and Aiolos proteins, inducing apoptosis in multiple myeloma cells and stimulating the immune system. The future of CELMoDs like mezigdomide looks promising as they continue to show high synergy with traditional partners and advanced treatments. Get detailed analysis of the abstract here @ https://lnkd.in/eq2-MY47 Stay tuned for more updates! #MultipleMyeloma #ClinicalTrials #Mezigdomide #BMS #CancerResearch #CELMoDs #healthcare #business #clinicalstudies #clinicaltrials #results #phases #top #abstracts #myeloma #oncology #pharmacautical #hematology

Don’t miss the presentation titled, “Key Financial Viability Considerations for Laboratorians Considering Bringing Clinical Pharmacogenomics (PGx) Testing into the Laboratory with Live Q&A” on May 15 at 2:00 PM PDT. Becky Winslow, BS, PharmD will discuss how labs can financially benefit from implementing pharmacogenomics (PGx) testing by designing test panels and utilizing tests aligned with insurance coverage and reimbursement guidelines. Register now to learn more: https://buff.ly/3TYPbjU #LRprecisionmed

💊 We recognize that adverse drug reactions, or ADRs, can significantly impact healthcare systems and patient outcomes. That is why pharmacogenomics is continuing to play a pivotal role in advancing precision medicine. Pharmacogenomics leverages genetic insights, allowing labs and clinicians to tailor medications and prescriptions to each patient’s unique profile, mitigating the risks associated with ADRs. 💥 Want to see how VSPGx can empower your lab to offer more actionable clinical insights and reduce ADRs? Visit our site to learn more: https://lnkd.in/gkTBqxqj #Pharmacogenomics #Pharmacogenetics #PrecisionMedicine #GoldenHelix #VSPGx #HealthcareInnovation #ADRs #AdverseDrugReactions

Webinar alert from the PCSIG "Perceptions and acceptability of #microsampling for remote monitoring in patients with plasma cell dyscrasias" #Multiplemyeloma is categorized as a relapsing-remitting #bloodcancer and requires frequent blood tests. Microsampling introduces a self-administered, blood sampling technique that has potential to revolutionize multiple myeloma monitoring. Here, Nithya Paranthaman, PhD (The Royal Marsden NHS Foundation Trust) will discuss how patient and public involvement (PPI) was incorporated into studies, providing insightful feedback to support the view that microsampling would be a welcome addition to the routine clinical care of multiple myeloma. Thank-you to the PCSIG sponsors for supporting our activities - Altasciences; Alturas Analytics, Inc.;Artyc; BENTO BIOLOGY PLATFORMS; Boehringer Ingelheim; Capitainer; Charles River Laboratories; Genentech;GSK; IQVIA; MSD; Neoteryx; Pfizer; RedDrop Dx; Resolian; Roche; Slope; Takeda; Tasso, Inc., Veloxity Labs, LLC; Waters Corporation #patientcentricity #patientcentricsampling

Multiple myeloma is a promising therapeutic target due to the widespread expression of BCMA on myeloma cells. The field of BCMA-targeting drugs in multiple myeloma has undergone significant advancement. Introduction of CAR-T cell therapies ABECMA and CARVYKTI, and most recently TECVAYLI, are examples of the rise of the BCMA space in multiple myeloma. Regeneron’s Linvoseltamab is a BCMAxCD3 bispecific antibody in the pipeline for patients with RRMM. In February 2024, the US FDA accepted for Priority Review the BLA for linvoseltamab for RRMM that has progressed after at least three prior therapies, with a target action date for the FDA decision is August 22, 2024. In addition to this, it is also under review for R/R MM by the EMA with EC decision on the regulatory submission of linvoseltamab for the treatment of adult patients with RRMM is planned for the first half of 2025. Experience Expert Insights and Comprehensive Analysis with DelveInsight Business Research LLP's European Hematology Association (EHA) 2024 Coverage @ https://lnkd.in/gR9FxYKJ #MultipleMyeloma #BCMA #ABECMA #CARVYKTI #TECVAYLI #CARTtherapy #oncology #cancerresearch #Linvoseltamab #Regeneron #RRMM #FDAapproval #PriorityReview #BLA #EMA #biopharma #medicalinnovation #treatmentoptions #healthcarenews #drugpipeline

In ONCO Life's featured interview of the principal investigator of GenFleet's KROCUS study, Dr. Rafael Rosell analyzed the favorable efficacy and safety of this first-line combination therapy. The phase II trial data of KROCUS Study, fulzerasib (KRAS G12C inhibitor) in combination with cetuximab (EGFR inhibitor), was orally presented at ASCO annual meeting in June. "Notably, in our study, about 32.5% of patients had brain metastases at the start of the treatment, which is particularly challenging as brain metastases usually correlate with poor survival and quality of life. Impressively, 70% of these patients showed a response without the need for brain irradiation. The ability to combine these new KRAS inhibitors with established treatments can potentially prolong survival significantly. This was evidenced in the KROCUS study, where we observed promising response rates and anticipate longer durations of response with these combinations." Please view the full text from page 7 of the online magazine, at the link of https://lnkd.in/gu9tW4XW For more of GenFleet's information, please visit the official website at

We are thrilled to announce that AC Immune and Takeda have won the #Deal of the Year (>€500M) at the European Lifestars Awards - Celebrating Life Science Leaders. This recognition highlights our transformative license and option agreement centered on ACI-24.060, our active immunotherapy candidate targeting toxic forms of amyloid beta in Alzheimer’s disease. Currently under evaluation in the ABATE Phase 1b/2 trial, ACI-24.060 has also received Fast Track designation from the U.S. FDA, emphasizing its potential to address this critical unmet medical need. This #partnership with Takeda embodies our commitment to pioneering precision prevention for neurodegenerative diseases. Thank you to our dedicated team at AC Immune and our partners at Takeda for making this possible. Together, we will reshape the future of #Alzheimer’s #treatment and #prevention. #Neurodegeneration #PrecisionMedicine #Award #Biotech #Biopharma

Biomarker-driven clinical trials are key to advancing #precisionmedicine. Yet, deriving clinically relevant insights from complex multimodal #data is not trivial. Read the case study below to learn how MacroGenics leveraged our #software solution and the #bioinformatics expertise of our team to get the most out of their data and advance the clinical development of their #immunotherapy. https://lnkd.in/eMhs8eRk #GenedataProfiler #PathToPrecision

Douglas Paul, VP of Commercial Strategy & Founder of Cypress BioPharma, and our President & CEO, Chris Smith, led a workshop recently at the 4th Annual Rare & Genetic Kidney Disease Drug & Development Summit in Boston titled, “Commercialization & Communication Through the Clinical Experience in the Rare & Genetic Kidney Disease Space.”   Doug and Chris outlined steps for understanding the needs of patient communities, communicating the value of promising treatments, and discussing drug prices in the context of today’s healthcare system. They explored reimbursement trends and surfaced ways to align payers, policy makers, physicians, and industry in a common goal of improving health.  #raredisease #genetherapy #kidneydisease

B-cell CAR-T cell therapies have garnered much attention, but the T-cell segment remains untapped. T-ALL, prevalent among adolescents and young adults, lacks effective therapies. Traditional chemotherapy shows good initial responses, yet relapse rates remain high, with poor survival outcomes for relapsed/refractory cases. WU-CART-007, a CD7-targeted CAR-T cell therapy by Wugen, leverages CRISPR/Cas9 to delete CD7 and the T-cell receptor alpha constant, mitigating fratricide and utilizing healthy donor allogeneic T-cells. Promising data from the Phase I/II trial, presented at the 2023 American Society of Hematology and European Hematology Association (EHA) 2024 congress, showed a composite complete remission rate (CRc) of 73% at the recommended Phase 2 dose (RP2D). Key outcomes include a 91% overall response rate (ORR) and a manageable safety profile. These results suggest WU-CART-007's potential to surpass current treatments like nelarabrine for relapsed/refractory T-ALL/LBL. Regulatory designations, such as RMAT and PRIME, highlight its promise. A follow-up study, including pediatric patients and a minimal residual disease (MRD) cohort, is slated to start in Q4 2024. Read detailed analysis of the abstract here @ https://lnkd.in/gRBNGKfQ #CART #TALL #WUCART007 #Hematology #Wugen #EHA2024 #ASH2023 #CancerResearch #EHA2024 #EHA24 #healthcare #business #clinicalstudies #clinicaltrials #results #phases #top #abstracts #multiplemyeloma #pharmacautical #hematology